Clear Cell Renal Cell Carcinoma 2021–2022

Download Url(s)
https://mdpi.com/books/pdfview/book/6216Contributor(s)
Manini, Claudia (editor)
López, José I. (editor)
Language
EnglishAbstract
Clear cell renal cell carcinoma is currently one of the most interesting areas of study in oncology. Despite the advances made in this field, this tumor continues to be a health problem of major concern in Western societies, seriously affecting public health services. Several characteristics of this tumor make it an exciting meeting point for translational collaboration between clinicians and basic researchers. Clear cell renal cell carcinoma is a paradigmatic example of inter- and intra-tumor heterogeneity from morphological, immunohistochemical, and molecular viewpoints. This tumor is also a good example to investigate the complexity of tumor/tumor and tumor/environment relationships from an ecological perspective. A deeper identification of the varied internal tumor self-organization through the specialization of cell clones and subclones as local invaders and metastasizers, on one hand, and the interactions of specific subsets of tumor cells with the local host microenvironment, on the other, will significantly enrich our knowledge of this neoplasm. Clear cell renal cell carcinoma is also a paradigmatic test bench for antiangiogenic and immune checkpoint blockage therapies. The refinement of these therapeutic tools administered alone or in combination is a hot issue in oncology, and several international trials are underway.
Keywords
clear cell renal cell carcinoma; prognosis; plasma; PD-1; PD-L1; renal cell carcinoma; immune checkpoint inhibitors; immune related adverse events (irAEs); thyroid; cutaneous; biomarker; DNA methylation; epigenetics; kidney; hypoxia; tumor microenvironment; SCD-1; oleic acid; renal cancer; sunitinib; resistance; miRNA; transcriptome; pathway analysis; nivolumab; tissue slice culture; PD1; T-cells; metastatic clear cell renal cell carcinoma; first-line treatment; immunotherapy; tyrosine kinase inhibitors; combinations; single-cell RNA sequencing; immune landscape; cancer immunotherapy; intra-tumoral heterogeneity; inter-tumoral heterogeneity; inter-metastatic heterogeneity; renal cell cancer; treatment resistance; angiogenesis; adjuvant therapy; prediction model; prognostic factor; clear cell kidney cancer; radiogenomics; radiomics; machine learning; gene expression; cystic tumor; imaging; magnetic resonance; surgery; ddPCR; circulating miRNA; diagnosis; malignancy; histomorphological features; PBRM1; immunohistochemistry; architectural patterns; endothelial cells; translational; immune checkpoint inhibitor; responsiveness; molecular features; multisite tumor sampling; intratumor heterogeneity; clear-cell renal cell carcinoma; disease progression; prognostic factors; biomarkers; RNA sequencing; n/aWebshop link
https://mdpi.com/books/pdfview ...ISBN
9783036555188, 9783036555171Publisher website
www.mdpi.com/booksPublication date and place
Basel, 2022Classification
Medicine and Nursing
Clinical and internal medicine